193 related articles for article (PubMed ID: 10669005)
41. GFAP promoter driven transgenic expression of PDGFB in the mouse brain leads to glioblastoma in a Trp53 null background.
Hede SM; Hansson I; Afink GB; Eriksson A; Nazarenko I; Andrae J; Genove G; Westermark B; Nistér M
Glia; 2009 Aug; 57(11):1143-53. PubMed ID: 19115382
[TBL] [Abstract][Full Text] [Related]
42. IGFBP2 is a candidate biomarker for Ink4a-Arf status and a therapeutic target for high-grade gliomas.
Moore LM; Holmes KM; Smith SM; Wu Y; Tchougounova E; Uhrbom L; Sawaya R; Bruner JM; Fuller GN; Zhang W
Proc Natl Acad Sci U S A; 2009 Sep; 106(39):16675-9. PubMed ID: 19805356
[TBL] [Abstract][Full Text] [Related]
43. Astrocyte-specific expression of CDK4 is not sufficient for tumor formation, but cooperates with p53 heterozygosity to provide a growth advantage for astrocytes in vivo.
Huang ZY; Baldwin RL; Hedrick NM; Gutmann DH
Oncogene; 2002 Feb; 21(9):1325-34. PubMed ID: 11857076
[TBL] [Abstract][Full Text] [Related]
44. The role of Ink4a/Arf in ErbB2 mammary gland tumorigenesis.
D'Amico M; Wu K; Di Vizio D; Reutens AT; Stahl M; Fu M; Albanese C; Russell RG; Muller WJ; White M; Negassa A; Lee HW; DePinho RA; Pestell RG
Cancer Res; 2003 Jun; 63(12):3395-402. PubMed ID: 12810676
[TBL] [Abstract][Full Text] [Related]
45. Determination of p53 mutations, EGFR overexpression, and loss of p16 expression in pediatric glioblastomas.
Sure U; Rüedi D; Tachibana O; Yonekawa Y; Ohgaki H; Kleihues P; Hegi ME
J Neuropathol Exp Neurol; 1997 Jul; 56(7):782-9. PubMed ID: 9210874
[TBL] [Abstract][Full Text] [Related]
46. Modeling gliomagenesis with somatic cell gene transfer using retroviral vectors.
Uhrbom L; Holland EC
J Neurooncol; 2001 Jul; 53(3):297-305. PubMed ID: 11718262
[TBL] [Abstract][Full Text] [Related]
47. Gliomagenesis: genetic alterations and mouse models.
Holland EC
Nat Rev Genet; 2001 Feb; 2(2):120-9. PubMed ID: 11253051
[TBL] [Abstract][Full Text] [Related]
48. Orthotopic transplantation of v-src-expressing glioma cell lines into immunocompetent mice: establishment of a new transplantable in vivo model for malignant glioma.
Smilowitz HM; Weissenberger J; Weis J; Brown JD; O'Neill RJ; Laissue JA
J Neurosurg; 2007 Apr; 106(4):652-9. PubMed ID: 17432718
[TBL] [Abstract][Full Text] [Related]
49. Patterns of epidermal growth factor receptor amplification in malignant gliomas.
Sauter G; Maeda T; Waldman FM; Davis RL; Feuerstein BG
Am J Pathol; 1996 Apr; 148(4):1047-53. PubMed ID: 8644846
[TBL] [Abstract][Full Text] [Related]
50. Double minute amplification of mutant PDGF receptor α in a mouse glioma model.
Zou H; Feng R; Huang Y; Tripodi J; Najfeld V; Tsankova NM; Jahanshahi M; Olson LE; Soriano P; Friedel RH
Sci Rep; 2015 Feb; 5():8468. PubMed ID: 25683249
[TBL] [Abstract][Full Text] [Related]
51. PTEN decreases in vivo vascularization of experimental gliomas in spite of proangiogenic stimuli.
Abe T; Terada K; Wakimoto H; Inoue R; Tyminski E; Bookstein R; Basilion JP; Chiocca EA
Cancer Res; 2003 May; 63(9):2300-5. PubMed ID: 12727853
[TBL] [Abstract][Full Text] [Related]
52. Primary glioblastomas with and without EGFR amplification: relationship to genetic alterations and clinicopathological features.
Benito R; Gil-Benso R; Quilis V; Perez M; Gregori-Romero M; Roldan P; Gonzalez-Darder J; Cerdá-Nicolas M; Lopez-Gines C
Neuropathology; 2010 Aug; 30(4):392-400. PubMed ID: 20051017
[TBL] [Abstract][Full Text] [Related]
53. Isolation of immortalized, INK4a/ARF-deficient cells from the subventricular zone after in utero N-ethyl-N-nitrosourea exposure.
Savarese TM; Jang T; Low HP; Salmonsen R; Litofsky NS; Matuasevic Z; Ross AH; Recht LD
J Neurosurg; 2005 Jan; 102(1):98-108. PubMed ID: 15658102
[TBL] [Abstract][Full Text] [Related]
54. The contribution of tumor and host tissue factor expression to oncogene-driven gliomagenesis.
Magnus N; Meehan B; Garnier D; Hashemi M; Montermini L; Lee TH; Milsom C; Pawlinski R; Ohlfest J; Anderson M; Mackman N; Rak J
Biochem Biophys Res Commun; 2014 Nov; 454(2):262-8. PubMed ID: 25450387
[TBL] [Abstract][Full Text] [Related]
55. An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor.
Kambara H; Okano H; Chiocca EA; Saeki Y
Cancer Res; 2005 Apr; 65(7):2832-9. PubMed ID: 15805284
[TBL] [Abstract][Full Text] [Related]
56. Loss of Tsc1 accelerates malignant gliomagenesis when combined with oncogenic signals.
Yamada D; Hoshii T; Tanaka S; Hegazy AM; Kobayashi M; Tadokoro Y; Ohta K; Ueno M; Ali MA; Hirao A
J Biochem; 2014 Apr; 155(4):227-33. PubMed ID: 24368778
[TBL] [Abstract][Full Text] [Related]
57. Human glioblastoma xenografts overexpressing a tumor-specific mutant epidermal growth factor receptor sensitized to cisplatin by the AG1478 tyrosine kinase inhibitor.
Nagane M; Narita Y; Mishima K; Levitzki A; Burgess AW; Cavenee WK; Huang HJ
J Neurosurg; 2001 Sep; 95(3):472-9. PubMed ID: 11565870
[TBL] [Abstract][Full Text] [Related]
58. Rapid and robust transgenic high-grade glioma mouse models for therapy intervention studies.
de Vries NA; Bruggeman SW; Hulsman D; de Vries HI; Zevenhoven J; Buckle T; Hamans BC; Leenders WP; Beijnen JH; van Lohuizen M; Berns AJ; van Tellingen O
Clin Cancer Res; 2010 Jul; 16(13):3431-41. PubMed ID: 20472681
[TBL] [Abstract][Full Text] [Related]
59. Surface-immobilized aptamers for cancer cell isolation and microscopic cytology.
Wan Y; Kim YT; Li N; Cho SK; Bachoo R; Ellington AD; Iqbal SM
Cancer Res; 2010 Nov; 70(22):9371-80. PubMed ID: 21062984
[TBL] [Abstract][Full Text] [Related]
60. In vitro identification and functional characterization of glial precursor cells in human gliomas.
Colin C; Baeza N; Tong S; Bouvier C; Quilichini B; Durbec P; Figarella-Branger D
Neuropathol Appl Neurobiol; 2006 Apr; 32(2):189-202. PubMed ID: 16599947
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
